Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.58347/tml.2023.1668c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate.
Expert Rev Clin Immunol
June 2023
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Introduction: Allergic rhinitis (AR) is a common disease with an important impact on the quality of life and very high management costs. In many patients, the poor control of rhinitis symptoms often requires the use of different drugs, and polytherapy tends to reduce therapeutic adherence. According to the latest version of ARIA guidelines, the currently recommended drugs for the treatment of moderate-to-severe AR are second-generation antihistamines, intranasal corticosteroids, and their combination, even in a single nasal spray device.
View Article and Find Full Text PDFIntranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis.
Ann Pharmacother
May 2023
Infectious Diseases, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, and Ascension St. John Hospital, Detroit, MI, USA.
Objective: To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR).
Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: mometasone + olopatadine, GSP301, mometasone furoate, and olopatadine hydrochloride.
Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis.
Eur Arch Otorhinolaryngol
April 2022
Bengbu Medical College Graduate Department, Bengbu, China.
Purpose: GSP301 is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). This meta-analysis aims to evaluate the efficacy and safety of GSP301 in the treatment of allergic rhinitis.
Methods: A systematic review and meta-analysis were conducted.
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Ann Allergy Asthma Immunol
February 2020
Glenmark Pharmaceuticals Inc, Paramus, New Jersey.
Background: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).
Objective: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR).
Methods: In this phase 2, double-blind, parallel-group study, patients (≥12 years of age) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665 μg and mometasone 25 μg), once-daily GSP301 (olopatadine 665 μg and mometasone 50 μg), twice-daily or once-daily olopatadine monotherapy (665 μg), mometasone monotherapy (twice-daily 25 μg or once-daily 50 μg), or placebo for 14 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!